In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Light_Bulbs

Technological And Scientific Advances Offer The Main Route To Solving The Growing Needs Of Patients

EU Health Innovation Partnership Reflects Medtech’s Role In Unmet Needs

MedTech Europe’s Director Of European Research & Innovation Partnership Policies Explains The Prize At Stake In A Unique Project For Medtechs

Executive Summary

The EU Partnership on Health Innovation, a new public private health care research partnership, is in the final drafting phase before its launch under Horizon Europe. In Vivo asked the partnership’s medtech industry lead, Patrick Boisseau, to set out the innovation challenges for participants as they address unmet health care needs in Europe.

You may also be interested in...



Stark COVID-19 Drug Shortages Warning From Senior EU Regulator

The deputy head of the European Medicines Agency has outlined the steps the agency is taking to assess and address the possibility of drug shortages in Europe caused by the coronavirus outbreak, as the number of cases worldwide tops the 98,000 mark. 

UK Government Promise For 2021: No Halting The Advance Of Healthtech Innovation Adoption

There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.

UK Medtechs Determined To Exploit Digital Health Opportunity Born From The Pandemic

COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel